News & Events > News > Qritive Secures Multi-Year Contracts with Metropolis Healthcare, CŌRE Diagnostics and Rajiv Gandhi Cancer Institute

Qritive Secures Multi-Year Contracts with Metropolis Healthcare, CŌRE Diagnostics and Rajiv Gandhi Cancer Institute

QritiveTM, a leading provider of AI solutions for pathology labs worldwide, proudly announces its partnership with three esteemed diagnostic centres and hospitals in India: Metropolis Healthcare, Rajiv Gandhi Cancer Institute and CŌRE Diagnostics. These institutions have embraced PantheonTM image management system (IMS) and Qritive’s AI products, marking them as trailblazers in the adoption of artificial intelligence in pathology workflows.

The integration of Qritive’s AI technology into the diagnostic processes of these world-class diagnostic centres and hospitals represents a significant leap forward in the modernization of pathology practices. By leveraging the power of artificial intelligence, these institutions are enhancing diagnostic accuracy, improving operational efficiency, and ultimately advancing patient care.

Commenting on the partnership, Mr Surendran Chemmenkottil, CEO, of Metropolis Healthcare, stated: “As we embark on this transformative journey with Qritive, we are enthusiastic about the immense potential it holds for advancing our capabilities in pathology. The integration of Qritive’s AI-powered platform into our workflows signifies a revolutionary step in enhancing precision, timeliness, and personalized diagnosis. This collaboration reinforces our commitment to setting a new standard in cancer care, particularly in supporting clinicians in making effective treatment decisions for prostate cancer detection.”

“Qritive is proud to have the opportunity to work alongside such forward-looking healthcare institutions, seizing the power of AI to improve patient outcomes and concurrently enhance the life of their pathologists. Our whole team is eager to showcase how deep tech will support clinicians and contribute to “closing the gap” in cancer care, meeting the aspirations of the World Cancer Day of February 4th.” said Bruno Occhipinti, CEO of Qritive.

“We’re thrilled to partner with Qritive, integrating their advanced AI solutions into our pathology workflow at CŌRE Diagnostics. This collaboration will strengthen our diagnostic precision, resulting in improved patient outcomes, and reaffirm our dedication to delivering excellence in clinical care. The collaboration also has the potential to lead to the development of new AI services for the diagnosis of rare diseases.” said Mr Dinesh Chauhan, CEO of CŌRE Diagnostics.

The implementation of Qritive’s AI-powered platform significantly transforms pathology workflows. Clinical studies carried out at prominent healthcare institutions reveal up to 90% reduction in the time needed for diagnoses and up to 80% decrease in discordance among pathologists. Such improvements lead to increased diagnostic accuracy and an overall enhancement in the quality of care for cancer patients.

“Qritive’s IMS and AI modules have enhanced our pathology practice at RGCI. With efficient identification of concerning areas and precise grading, integrating these tools has enhanced our workflow and diagnostic precision, offering significant benefits to our practice.” – Dr Gurudutt Gupta, HOD Pathology at Rajiv Gandhi Cancer Institute Research Centre.

About Qritive:

Headquartered in Singapore, with operations in the US & India, Qritive is a breakthrough Artificial Intelligence (AI) solution developer that is advancing digital pathology for cancer diagnosis and improving health outcomes with the assistance of AI-based solutions. Qritive expands on deep learning technology to support the interpretation of pathology tests for time and resource-strapped medical imaging professionals – enabling faster diagnosis and reducing time to treatment for patients. Qritive is dedicated to empowering healthcare professionals across the globe with AI-powered solutions to operate collaboratively at the peak of their performance despite complexity and distance.

For media inquiries, please contact:

Shriya Kumar, Business Development & Partnership Manager,

About Metropolis:

About Metropolis Healthcare Limited:

Established in 1981, Metropolis Healthcare Limited is a leading diagnostics company in India with a widespread presence in 20 states & 220 cities. Internationally, the company has a presence in South Asia, Africa, and the Middle East. Metropolis touches millions of lives each year by providing actionable health insights to patients and doctors. Metropolis offers a comprehensive range of 4,000 plus tests and profiles that include advanced tests in the diagnosis of cancer, neurological disorders, infectious diseases, and an array of genetic abnormalities. The company is empowered with a robust network of over 180 labs, 3900 collection centres and 1000+ touch points. Metropolis’ commitment to quality and accuracy in each test is reinforced by its consistent CAP proficiency score of more than 98% over the past decade, which places it amongst the top 1% of laboratories worldwide for quality assurance. Metropolis philosophy rests on the pillars of technological superiority, a warm patient-centric approach and reliable diagnostic reports. For more information, please visit or follow us on Twitter, Facebook, or LinkedIn.

About CŌRE Diagnostics:

CŌRE Diagnostics is a leading name in High-end and specialized diagnostics in India, with its reference lab in Gurugram along with its satellite labs in Delhi, Lucknow, Guwahati, Bhubaneswar, Hyderabad, and Bengaluru.

Internationally, CŌRE Diagnostics has partners from Dubai, Iraq, Kuwait, Myanmar, Nepal, Nigeria, Sri Lanka, Uganda & Uzbekistan. CŌRE Diagnostics is a CAP and NABL Accredited laboratory chain, with Board-certified pathologists and a group of organ-specific onco-pathologists along with a Clinical Biobank and Disease Data Bank. CŌRE Diagnostics offers comprehensive testing in the areas of Oncology and Non-Oncology somatic and germline (hereditary) disorders, Neurology, Reproductive medicine, Transplant pathology, Infectious & Rare Diseases.  It works with State Governments, Pharma majors, CROs, and Government Research Organisations on various research projects.

CŌRE Diagnostics leverages the latest technology to provide accurate and timely analyses across a diverse range of healthcare specialities and empowers healthcare professionals with reliable data to inform optimal patient care. Committed to personalized medicine, CŌRE Diagnostics’s innovative approach and patient-centric focus position it as a key player in advancing healthcare outcomes. For more information, please visit or follow us on Linkedin, Youtube, Instagram, Facebook & Twitter.

About Rajiv Gandhi Cancer Institute:

Rajiv Gandhi Cancer Institute and Research Centre is a non-profit medical facility and research institute based in Delhi, India specialising in cancer treatment and research. It is one of the largest medical centres for cancer treatment in Asia.

Our Newsletter

Subscribe to our newsletter to get timely updates on latest news and articles.

Join our team

Join us and build products for cancer diagnosis. We are looking for great people to join our growing team.
Back to top

and modern

Contemporary theme especially made for technology & software developing company websites. Deon, a new age of WP design.